Related Experiment Video
Updated: May 11, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Challenges in pharmacogenetics
Ingolf Cascorbi1, Oliver Bruhn, Anneke N Werk
1Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. cascorbi@pharmakologie.uni-kiel.de
European Journal of Clinical Pharmacology
|May 4, 2013
Summary
Pharmacogenetics (PGx) optimizes drug treatment by analyzing genetic information. Advances in pharmacogenomics, especially in oncology, integrate genetics, epigenetics, and environmental factors for personalized medicine.
Area of Science:
- Genomic Medicine
- Oncology
- Translational Science
Background:
- Evidence-based medicine optimizes drug treatment using individual patient data.
- Pharmacogenetics (PGx) uses hereditary genetic information for personalized medicine.
- Pharmacogenomics is increasingly vital in modern oncology.
Purpose of the Study:
- To review current challenging and promising examples of pharmacogenetics (PGx).
- To highlight the role of new technologies in understanding genetic variation.
- To emphasize the integration of genetics, epigenetics, and gene-environmental interactions.
Main Methods:
- Review of current literature on pharmacogenetics (PGx).
- Analysis of advancements in next-generation sequencing.
- Evaluation of computational and information sciences in pharmacogenomics.
Main Results:
- Pharmacogenetics (PGx) enables personalized drug treatment.
- Pharmacogenomics is crucial for advancing cancer treatment.
- New technologies facilitate understanding of genetic variation's clinical impact.
Conclusions:
- Pharmacogenetics (PGx) is essential for personalized medicine, particularly in oncology.
- Integrating genetics, epigenetics, and environmental factors improves treatment outcomes.
- Future research should focus on translating genetic insights into clinical practice.
Related Concept Videos
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...